• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Adverse reactions of drugs specifically used for treatment of SARS-CoV-2 infection.专门用于治疗新型冠状病毒2型感染的药物的不良反应。
Med Clin (Engl Ed). 2020 Nov 27;155(10):448-453. doi: 10.1016/j.medcle.2020.06.026. Epub 2020 Oct 30.
2
Adverse reactions of drugs specifically used for treatment of SARS-CoV-2 infection.专门用于治疗 SARS-CoV-2 感染的药物的不良反应。
Med Clin (Barc). 2020 Nov 27;155(10):448-453. doi: 10.1016/j.medcli.2020.06.019. Epub 2020 Jul 9.
3
COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.COVID-19 疫苗:辉瑞/生物科技和 Moderna 疫苗的生物学、药理学特征和不良反应比较。
Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1663-1669. doi: 10.26355/eurrev_202102_24877.
4
Inappropriate risk perception for SARS-CoV-2 infection among Italian HCWs in the eve of COVID-19 pandemic.在新冠疫情前夕,意大利医护人员对新冠病毒感染存在不当的风险认知。
Acta Biomed. 2020 May 14;91(3):e2020040. doi: 10.23750/abm.v91i3.9727.
5
High prevalence of SARS-CoV-2 infection among symptomatic healthcare workers in a large university tertiary hospital in São Paulo, Brazil.巴西圣保罗一家大型大学附属医院出现症状的医护人员中 SARS-CoV-2 感染的高流行率。
BMC Infect Dis. 2020 Dec 2;20(1):917. doi: 10.1186/s12879-020-05662-8.
6
Clinical trials and the COVID-19 pandemic.临床试验与新冠疫情
Hell J Nucl Med. 2020 Jan-Apr;23(1):4-5. doi: 10.1967/s002449912014.
7
The theoretical mortality risk of an asymptomatic patient with a negative SARS-CoV-2 test developing COVID-19 following elective orthopaedic surgery.无症状且 SARS-CoV-2 检测结果为阴性的患者在择期骨科手术后发生 COVID-19 的理论死亡风险。
Bone Joint J. 2020 Sep;102-B(9):1256-1260. doi: 10.1302/0301-620X.102B9.BJJ-2020-1147.R1. Epub 2020 Jul 6.
8
Transmission risk of SARS-CoV-2 to healthcare workers -observational results of a primary care hospital contact tracing.SARS-CoV-2 对医护人员的传播风险-基层医疗机构接触者追踪的观察结果。
Swiss Med Wkly. 2020 Apr 25;150:w20257. doi: 10.4414/smw.2020.20257. eCollection 2020 Apr 20.
9
Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.从已批准的抗病毒药物中通过对接和虚拟筛选发现有效的 SARS-CoV-2 抑制剂。
Comb Chem High Throughput Screen. 2021;24(3):441-454. doi: 10.2174/1386207323999200730205447.
10
Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.新型冠状病毒灭活疫苗在安全性和免疫原性方面的效果:两项随机临床试验的中期分析。
JAMA. 2020 Sep 8;324(10):951-960. doi: 10.1001/jama.2020.15543.

引用本文的文献

1
Use of Ivermectin and Chlorine Dioxide for COVID-19 Treatment and Prophylaxis in Peru: A Narrative Review.伊维菌素和二氧化氯在秘鲁用于治疗和预防 COVID-19:一项叙述性综述。
Cureus. 2022 Nov 23;14(11):e31836. doi: 10.7759/cureus.31836. eCollection 2022 Nov.
2
Safety, Tolerability, and Pharmacokinetics of Intravenous Doses of PF-07304814, a Phosphate Prodrug Protease Inhibitor for the Treatment of SARS-CoV-2, in Healthy Adult Participants.PF-07304814(一种用于治疗 SARS-CoV-2 的磷酸前药蛋白酶抑制剂)在健康成年参与者中的静脉剂量的安全性、耐受性和药代动力学。
Clin Pharmacol Drug Dev. 2022 Dec;11(12):1382-1393. doi: 10.1002/cpdd.1174. Epub 2022 Oct 26.
3
COVID-19 and the potential of Janus family kinase (JAK) pathway inhibition: A novel treatment strategy.2019冠状病毒病与 Janus 激酶(JAK)通路抑制的潜力:一种新的治疗策略。
Front Med (Lausanne). 2022 Aug 30;9:961027. doi: 10.3389/fmed.2022.961027. eCollection 2022.
4
Characterisation of Drug-Induced Liver Injury in Patients with COVID-19 Detected by a Proactive Pharmacovigilance Program from Laboratory Signals.通过实验室信号主动药物警戒计划检测到的 COVID-19 患者药物性肝损伤的特征分析
J Clin Med. 2021 Sep 27;10(19):4432. doi: 10.3390/jcm10194432.
5
Adverse reactions of drugs specifically used for treatment of SARS-CoV-2 infection.专门用于治疗新型冠状病毒2型感染的药物的不良反应。
Med Clin (Engl Ed). 2021 Jun 11;156(11):576. doi: 10.1016/j.medcle.2020.12.022. Epub 2021 Jun 5.
6
Adverse reactions of drugs specifically used for treatment of SARS-CoV-2 infection.专门用于治疗新型冠状病毒肺炎(SARS-CoV-2感染)的药物的不良反应。
Med Clin (Barc). 2021 Jun 11;156(11):576. doi: 10.1016/j.medcli.2020.12.013. Epub 2021 Jan 28.

本文引用的文献

1
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.瑞德西韦治疗成人重症 COVID-19 的随机、双盲、安慰剂对照、多中心临床试验。
Lancet. 2020 May 16;395(10236):1569-1578. doi: 10.1016/S0140-6736(20)31022-9. Epub 2020 Apr 29.
2
COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal.新冠病毒疾病在自然状态和免疫抑制状态下:一项临床治疗分期建议。
J Heart Lung Transplant. 2020 May;39(5):405-407. doi: 10.1016/j.healun.2020.03.012. Epub 2020 Mar 20.
3
Why tocilizumab could be an effective treatment for severe COVID-19?为什么托珠单抗可能是治疗严重 COVID-19 的有效方法?
J Transl Med. 2020 Apr 14;18(1):164. doi: 10.1186/s12967-020-02339-3.
4
Optimizing Hydroxychloroquine Dosing for Patients With COVID-19: An Integrative Modeling Approach for Effective Drug Repurposing.优化 COVID-19 患者的羟氯喹剂量:一种有效的药物再利用的综合建模方法。
Clin Pharmacol Ther. 2020 Aug;108(2):253-263. doi: 10.1002/cpt.1856. Epub 2020 May 12.
5
Compassionate Use of Remdesivir for Patients with Severe Covid-19.瑞德西韦在治疗重症 COVID-19 患者中的同情使用。
N Engl J Med. 2020 Jun 11;382(24):2327-2336. doi: 10.1056/NEJMoa2007016. Epub 2020 Apr 10.
6
Chloroquine and hydroxychloroquine in covid-19.氯喹和羟氯喹在2019冠状病毒病中的应用
BMJ. 2020 Apr 8;369:m1432. doi: 10.1136/bmj.m1432.
7
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.美国食品药品监督管理局批准的药物伊维菌素可抑制 SARS-CoV-2 的体外复制。
Antiviral Res. 2020 Jun;178:104787. doi: 10.1016/j.antiviral.2020.104787. Epub 2020 Apr 3.
8
Macrolide treatment for COVID-19: Will this be the way forward?大环内酯类药物治疗 COVID-19:这将是未来的方向吗?
Biosci Trends. 2020 May 21;14(2):159-160. doi: 10.5582/bst.2020.03058. Epub 2020 Apr 5.
9
Potential therapeutic agents against COVID-19: What we know so far.针对 COVID-19 的潜在治疗药物:目前我们所了解的情况。
J Chin Med Assoc. 2020 Jun;83(6):534-536. doi: 10.1097/JCMA.0000000000000318.
10
Could Chloroquine /Hydroxychloroquine Be Harmful in Coronavirus Disease 2019 (COVID-19) Treatment?氯喹/羟氯喹在2019冠状病毒病(COVID-19)治疗中会有害吗?
Clin Infect Dis. 2020 Jul 28;71(15):888-889. doi: 10.1093/cid/ciaa321.

专门用于治疗新型冠状病毒2型感染的药物的不良反应。

Adverse reactions of drugs specifically used for treatment of SARS-CoV-2 infection.

作者信息

Herrera-Lasso Regás Valeria, Dordal Culla María Teresa, Lleonart Bellfill Ramón

机构信息

Unitat d'Al·lergologia Servei de Medicina Interna, Hospital Universitari de Bellvitge, Barcelona, Spain.

出版信息

Med Clin (Engl Ed). 2020 Nov 27;155(10):448-453. doi: 10.1016/j.medcle.2020.06.026. Epub 2020 Oct 30.

DOI:10.1016/j.medcle.2020.06.026
PMID:33521297
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7834407/
Abstract

Currently, there is no treatment approved for COVID-19. Numerous drugs are being used in an empirical manner according to experience and availability. Studies demonstrating their efficacy and safety are still to be published. Thus, it is of vital importance for healthcare workers to be well informed and updated regarding possible immunological and non-immunological adverse effects regarding such treatments. In this narrative revision, the rationale use of these treatments in the SARS-CoV-2 infection is emphasized as well as their most frequently described adverse drug reactions. Drugs that are being essayed to counteract both clinical phases that are thought to take place in the severe stage of this disease are included; an initial phase where a viral infection prevails and a second phase where an inflammatory response takes over. Adverse reactions registered in the Pharmacovigilance Program of our hospital before the onset of this pandemic have also been included.

摘要

目前,尚无针对新冠肺炎的获批治疗方法。根据经验和可得性,许多药物正在被凭经验使用。证明其疗效和安全性的研究仍有待发表。因此,医护人员充分了解并及时掌握此类治疗可能产生的免疫和非免疫不良反应至关重要。在这篇叙述性综述中,强调了这些治疗方法在新型冠状病毒感染中的合理应用及其最常描述的药物不良反应。文中纳入了正在试验用于对抗该疾病重症阶段两个临床阶段的药物;第一个阶段以病毒感染为主,第二个阶段以炎症反应为主。还纳入了在本次大流行开始前在我院药物警戒计划中记录的不良反应。